Profectus BioSciences Raises $5 Million
Profectus BioSciences Inc., a Baltimore-based developer of vaccines for chronic viral infections, has raised $5 million in Series C funding. Return backer Cross Atlantic Capital Partners led the round, which brings the company's total venture capitalization to $19 million.
22 July 2009•3 mins read
